Premium
Reelin gene variants and risk of autism spectrum disorders: An integrated meta‐analysis
Author(s) -
Wang Zhenling,
Hong Yuan,
Zou Li,
Zhong Rong,
Zhu Beibei,
Shen Na,
Chen Wei,
Lou Jiao,
Ke Juntao,
Zhang Ti,
Wang Weipeng,
Miao Xiaoping
Publication year - 2014
Publication title -
american journal of medical genetics part b: neuropsychiatric genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.393
H-Index - 126
eISSN - 1552-485X
pISSN - 1552-4841
DOI - 10.1002/ajmg.b.32222
Subject(s) - reelin , odds ratio , meta analysis , confidence interval , autism spectrum disorder , autism , transmission disequilibrium test , heritability , medicine , genetics , gene , biology , single nucleotide polymorphism , genotype , psychiatry , receptor
Autism spectrum disorder (ASD) is a severe neurological disorder with a high degree of heritability. Reelin gene (RELN), which plays a crucial role in the migration and positioning of neurons during brain development, has been strongly posed as a candidate gene for ASD. Genetic variants in RELN have been investigated as risk factors of ASD in numerous epidemiologic studies but with inconclusive results. To clearly discern the effects of RELN variants on ASD, the authors conducted a meta‐analysis integrating case–control and transmission disequilibrium test (TDT) studies published through 2001 to 2013. Odds ratios (ORs) with 95% confidence intervals were used to estimate the associations between three RELN variants (rs736707, rs362691, and GGC repeat variant) and ASD. In overall meta‐analysis, the summary ORs for rs736707, rs362691, and GGC repeat variant were 1.11 [95% confidence interval (CI): 0.80–1.54], 0.69 (95% CI: 0.56–0.86), and 1.09 (95% CI: 0.97–1.23), respectively. Besides, positive result was also obtained in subgroup of broadly‐defined ASD for rs362691 (OR = 0.67, 95% CI: 0.52–0.86). Our meta‐analysis revealed that the RELN rs362691, rather than rs736707 or GGC repeat variant, might contribute significantly to ASD risk. © 2014 Wiley Periodicals, Inc.